[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:mki67-gene":3},{"name":4,"total":5,"recruiting":5,"trials":6},"MKI67 Gene",26,[7,15,22,28,34,41,48,55,61,67,73,79,85,91,97,103,109,115,121,127,133,139,145,151,157,163],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06148038","CBD for Breast Cancer Primary Tumors",[11],"Phase 1","RECRUITING","2026-08-26T02:15:44.309045Z","2026-05-05T02:43:29.410736Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06450873","Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery",[19],"Phase 2","2026-08-26T02:17:51.502023Z","2026-05-05T02:43:29.186687Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT06395402","177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry",[19],"2026-08-26T02:15:45.413021Z","2026-05-05T02:43:29.074931Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT07287098","A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer",[19],"2026-08-26T02:19:16.454910Z","2026-05-05T02:43:29.072318Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":39,"content_modified":40},"NCT03583710","Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence",[38],"Phase 3","2026-08-26T02:19:29.922117Z","2026-05-05T02:43:28.838020Z",{"nct_id":42,"title":43,"phases":44,"status":12,"updated_at":46,"content_modified":47},"NCT05464810","Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer",[45],"Early Phase 1","2026-08-26T02:18:47.742071Z","2026-05-05T02:43:28.826515Z",{"nct_id":49,"title":50,"phases":51,"status":12,"updated_at":53,"content_modified":54},"NCT06357676","Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",[52],"Phase 1\u002FPhase 2","2026-08-26T02:15:02.712396Z","2026-05-05T02:43:28.817702Z",{"nct_id":56,"title":57,"phases":58,"status":12,"updated_at":59,"content_modified":60},"NCT04609592","Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery",[11],"2026-08-03T01:59:18.089574Z","2026-05-05T02:43:28.703397Z",{"nct_id":62,"title":63,"phases":64,"status":12,"updated_at":65,"content_modified":66},"NCT05040360","Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors",[19],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:28.548908Z",{"nct_id":68,"title":69,"phases":70,"status":12,"updated_at":71,"content_modified":72},"NCT02476786","Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score",[19],"2026-08-26T02:17:17.791881Z","2026-05-05T02:43:28.420219Z",{"nct_id":74,"title":75,"phases":76,"status":12,"updated_at":77,"content_modified":78},"NCT05746208","Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors",[19],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:28.183234Z",{"nct_id":80,"title":81,"phases":82,"status":12,"updated_at":83,"content_modified":84},"NCT06897488","EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial",[19],"2026-08-26T02:19:28.327680Z","2026-05-05T02:43:27.982803Z",{"nct_id":86,"title":87,"phases":88,"status":12,"updated_at":89,"content_modified":90},"NCT05020860","Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer",[19],"2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.962723Z",{"nct_id":92,"title":93,"phases":94,"status":12,"updated_at":89,"content_modified":96},"NCT06016855","Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors",[95],"Phase 4","2026-05-05T02:43:27.860078Z",{"nct_id":98,"title":99,"phases":100,"status":12,"updated_at":101,"content_modified":102},"NCT07257055","Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study",[19],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.813302Z",{"nct_id":104,"title":105,"phases":106,"status":12,"updated_at":107,"content_modified":108},"NCT06263491","Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients",[19],"2026-08-26T02:17:55.355429Z","2026-05-05T02:43:27.392848Z",{"nct_id":110,"title":111,"phases":112,"status":12,"updated_at":113,"content_modified":114},"NCT07544654","A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy",[38],"2026-08-26T02:16:16.169331Z","2026-05-05T02:43:26.717266Z",{"nct_id":116,"title":117,"phases":118,"status":12,"updated_at":119,"content_modified":120},"NCT07054190","A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer",[19],"2026-08-26T02:15:03.757872Z","2026-05-05T02:35:31.905076Z",{"nct_id":122,"title":123,"phases":124,"status":12,"updated_at":125,"content_modified":126},"NCT06926634","Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)",[19],"2026-08-26T02:17:22.949982Z","2026-05-05T02:35:31.706749Z",{"nct_id":128,"title":129,"phases":130,"status":12,"updated_at":131,"content_modified":132},"NCT06202066","Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas",[19],"2026-08-03T02:57:18.103669Z","2026-05-05T02:43:29.222571Z",{"nct_id":134,"title":135,"phases":136,"status":12,"updated_at":137,"content_modified":138},"NCT06055439","A Phase 1\u002F2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy",[52],"2026-08-26T02:18:54.586325Z","2026-05-05T02:35:31.753376Z",{"nct_id":140,"title":141,"phases":142,"status":12,"updated_at":143,"content_modified":144},"NCT05652686","A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)",[52],"2026-08-26T02:16:14.341106Z","2026-07-19T19:36:05.121911Z",{"nct_id":146,"title":147,"phases":148,"status":12,"updated_at":149,"content_modified":150},"NCT05841563","Clinical Trial of PM54 in Advanced Solid Tumors Patients.",[11],"2026-08-26T02:15:18.897219Z","2026-05-05T02:43:26.706220Z",{"nct_id":152,"title":153,"phases":154,"status":12,"updated_at":155,"content_modified":156},"NCT06401421","EXActDNA-003 \u002F NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)",[],"2026-08-26T02:15:47.754948Z","2026-05-13T02:55:06.490797Z",{"nct_id":158,"title":159,"phases":160,"status":12,"updated_at":161,"content_modified":162},"NCT04090034","Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors",[],"2026-08-26T02:17:30.961790Z","2026-05-13T02:55:06.233960Z",{"nct_id":164,"title":165,"phases":166,"status":12,"updated_at":167,"content_modified":168},"NCT07132645","An Investigational Scan ([68Ga] Ga-FAPI-04 PET\u002FCT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer",[45],"2026-08-26T02:16:18.872924Z","2026-05-05T02:35:31.682913Z"]